Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have been given a consensus recommendation of “Buy” by the seven research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $4.75.

A number of research analysts recently issued reports on the stock. HC Wainwright set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, October 8th. Cantor Fitzgerald set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, October 26th. BidaskClub raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, January 11th. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, October 15th. Finally, Janney Montgomery Scott raised their price objective on BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a report on Friday, November 2nd.

Shares of BDSI opened at $4.59 on Friday. BioDelivery Sciences International has a one year low of $1.70 and a one year high of $4.74. The stock has a market capitalization of $325.02 million, a PE ratio of -11.77 and a beta of 0.53. The company has a quick ratio of 2.77, a current ratio of 3.00 and a debt-to-equity ratio of 1.42.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. The company had revenue of $14.16 million during the quarter, compared to the consensus estimate of $14.21 million. On average, research analysts forecast that BioDelivery Sciences International will post -0.59 earnings per share for the current fiscal year.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $3.72, for a total value of $29,760.00. Following the sale, the director now directly owns 514,187 shares of the company’s stock, valued at $1,912,775.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Sirgo sold 10,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Thursday, December 27th. The stock was sold at an average price of $2.91, for a total value of $29,100.00. Following the completion of the sale, the director now directly owns 2,489,542 shares in the company, valued at $7,244,567.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,336 shares of company stock worth $189,665. 13.26% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Point72 Asset Management L.P. grew its position in BioDelivery Sciences International by 150.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock worth $4,200,000 after purchasing an additional 900,000 shares in the last quarter. Wells Fargo & Company MN lifted its position in BioDelivery Sciences International by 121.7% during the 3rd quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock worth $331,000 after acquiring an additional 64,803 shares during the last quarter. Alpha Omega Wealth Management LLC acquired a new position in BioDelivery Sciences International during the 3rd quarter worth $3,668,000. JPMorgan Chase & Co. lifted its position in BioDelivery Sciences International by 35.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 267,874 shares of the specialty pharmaceutical company’s stock worth $750,000 after acquiring an additional 70,633 shares during the last quarter. Finally, BlackRock Inc. lifted its position in BioDelivery Sciences International by 2.7% during the 2nd quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock worth $3,512,000 after acquiring an additional 30,991 shares during the last quarter. 53.01% of the stock is currently owned by hedge funds and other institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Recommended Story: Quick Ratio

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.